Ascentage Pharma
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 6 months.
- Recent price momentum is -46.3% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 91.5% | Better than 97% |
| Operating margin | -208.6% | Better than 5% |
| Net margin | -216.5% | Better than 5% |
| Return on equity | -156.5% | Better than 4% |
| Return on invested capital | -48.3% | Better than 6% |
Momentum D-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -29.6% | Better than 18% |
| 6-month return | -43.0% | Better than 10% |
| 12-month return (ex latest month) | -51.3% | Better than 3% |
| Distance below 52-week high | 63.8% | Better than 9% |
Financial Health D
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.8x | Better than 51% |
| Debt to assets | 49.9% | Better than 15% |
| Interest coverage | -21.9x | Better than 9% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 250.9% | Better than 96% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 12.44
- Open
- 12.26
- Day range
- 11.97 - 12.26
- Avg price
- 12.20
- Volume
- 5.04K
- Turnover
- 61.48K
- Turnover ratei
- 0.01%
- Volume ratioi
- 0.90
- Amplitudei
- 2.33%
- 52-week rangei
- 11.97 - 33.09
Valuation
- P/Ei
- -5.99
- P/E (TTM)i
- -5.07
- P/Bi
- 13.39
- EPSi
- -2.00
- Book value / shi
- 0.89
- Net profit
- -186.50M
- Net assets
- 83.49M
Share structure
- Market cap
- 1.12B
- Float capi
- 868.55M
- Shares out
- 93.39M
- Float sharesi
- 72.56M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2025-01-24
63.8% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+17.54K net over the window
Short interest
- Shares short
- 9.13K
- % of floati
- 0.01%
- Days to coveri
- 1.03
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Ascentage Pharma (AAPG)?
Ascentage Pharma last traded at 11.97. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Ascentage Pharma's market cap?
About 1.12B.
What is the P/E ratio of Ascentage Pharma?
The trailing twelve-month P/E is -5.07. The Valuation tab shows it against the stock's own five-year range.
Does Ascentage Pharma pay a dividend?
Ascentage Pharma does not currently pay a regular dividend.
Is Ascentage Pharma a buy according to analysts?
The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 42.00, which implies 250.9% upside from the current price. This is not investment advice.
What is Ascentage Pharma's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Ascentage Pharma a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 20:02:37 · For reference only, not investment advice and not tailored to your situation.
Ascentage Pharma discussion 0 comments